Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company committed to discovering and developing new therapeutic treatments identified using its proprietary screening assay, today announced the appointment of Kathy Harrison, current General Manager of Dimerix Biosciences Pty Ltd (operating subsidiary of Dimerix Limited), to the role of Chief Executive Officer of Dimerix Limited.
Dimerix Chairman James Williams said, “We are delighted to appoint Kathy to this expanded role. In addition to driving key strategic outcomes from the recent-preIND meeting with the FDA and patent prosecution, Kathy has done a tremendous job establishing our phase II clinical program targeting chronic kidney disease, which is recruiting to schedule and on track to report final phase IIa data in the second half of 2017.”
“The Board looks forward to working with Kathy as we continue to deliver on our milestones. We believe Kathy has the international industry knowledge, expertise and leadership skills to take this business forward.”
Kathy has more than 20 years experience in a number of senior roles within the Australian biotechnology industry and listed companies with a focus on strategic commercial development of company intellectual property assets.
She has also worked for nine years in private practice as a patent and trade mark attorney gaining a wealth of experience in the legal framework underscoring commercialisation of new technologies.
Kathy holds a Master of Science from Manchester University (UK), a Certificate in Governance from the Governance Institute of Australia and is a Registered Patent and Trade Mark Attorney in Australia and Fellow of the Institute of Patent and Trade Mark Attorneys.
